Silymarin,an extract of milk thistle commonly used to treat chronic liver disease by millions of people around the World,does not offer significant improvements for patients,according to a new study conducted by a nationwide group of researchers including faculty at the Perelman School of Medicine at the University of Pennsylvania.













































